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anOBJECTIVES The purpose of this study was to determine whether bleeding risk varies depending on which P2Y12 re-
ceptor inhibitor agent is used.
BACKGROUND Prior studies have shown signiﬁcant bleeding risk among patients treated with triple therapy (i.e., oral
anticoagulant, P2Y12 receptor inhibitor, and aspirin).
METHODS We evaluated patients with acute myocardial infarction (MI) treated with percutaneous coronary interven-
tion (PCI) at 233 hospitals in the United States enrolled in the TRANSLATE-ACS (Treatment with Adenosine Diphosphate
Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome)
study (April 2010 to October 2012). Using inverse probability-weighted propensity modeling, we compared 6-month
adjusted risks of Bleeding Academic Research Consortium (BARC) bleeding, stratifying by whether or not bleeding
was associated with rehospitalization among patients discharged on aspirin þ anticoagulant þ clopidogrel (triple-C),
aspirin þ anticoagulant þ prasugrel (triple-P), aspirin þ clopidogrel (dual-C), or aspirin þ prasugrel (dual-P).
RESULTS Of 11,756 MI patients, 526 (4.5%) were discharged on triple-C, 91 (0.8%) on triple-P, 7,715 (66%) on dual-C,
and 3,424 (29%) on dual-P. Compared with dual-therapy patients, triple-therapy patients had signiﬁcantly higher any
BARC-deﬁned bleeding. Triple-P was associated with a greater risk of any BARC-deﬁned bleeding events compared with
triple-C. This ﬁnding was driven mostly by an increased risk of bleeding events that were patient-reported only and did
not require rehospitalization. There were no signiﬁcant differences in bleeding requiring rehospitalization between the
triple-P and -C groups.
CONCLUSIONS Among MI patients, the addition of an oral anticoagulant was associated with a signiﬁcantly greater risk
of any BARC-deﬁned bleeding relative to dual antiplatelet therapy, regardless of which P2Y12 receptor inhibitor was
selected. Among patients on triple therapy, prasugrel use was associated with higher patient-reported–only bleeding, but
not bleeding requiring rehospitalization, than clopidogrel-treated patients. (J Am Coll Cardiol Intv 2015;8:1880–9)
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AB BR E V I A T I O N S
AND ACRONYM S
BARC = Bleeding Academic
Research Consortium
CI = conﬁdence interval
DAPT = dual antiplatelet
therapy
GUSTO = Global Use of
Strategies to Open Occluded
Arteries
HR = hazard ratio
IRR = incidence rate ratio
MACE = major adverse cardiac
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1881D ual antiplatelet therapy (DAPT) with aspirinand a P2Y12 receptor inhibitor is standard ofcare following percutaneous coronary
intervention (PCI) for patients with acute myocardial
infarction (MI). However, approximately 5% to 10% of
patients who have acute MIs have conditions, such as
atrial ﬁbrillation or prosthetic valves, for which oral
anticoagulants provide superior beneﬁt when
compared with antiplatelet agents (1,2). Patients
with an indication for anticoagulant therapy on top
of DAPT represent a clinical conundrum, given the
lack of rigorous evidence supporting net clinical
beneﬁt with triple therapy use (3–5).SEE PAGE 1890
event(s)
MI = myocardial infarction
OR = odds ratio
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarctionPrevious studies of triple therapy have primarily
focused on clopidogrel, which has been the most
widely studied P2Y12 receptor inhibitor (6,7). Never-
theless, novel and more potent antiplatelet agents,
like prasugrel, are now in clinical use for patients
with acute MI treated with PCI (8,9). To date, there
is limited information on the relative effectiveness
and safety of clopidogrel versus prasugrel among
patients requiring triple therapy. The TRANSLATE-
ACS (Treatment with Adenosine Diphosphate Recep-
tor Inhibitors: Longitudinal Assessment of Treatment
Patterns and Events After Acute Coronary Syndrome)
study is a prospective, longitudinal, observational
study of patients in the United States who had either
ST-segment elevation myocardial infarction (STEMI)
or non-STEMI treated with PCI and a P2Y12 receptor
inhibitor during their index hospitalization. This
analysis of the TRANSLATE-ACS study population
was designed to address the following aims: 1)
describe the prevalence of triple therapy use with
clopidogrel versus prasugrel at discharge; 2) com-
pare clinical characteristics and outcomes between
patients receiving triple therapy versus DAPT; and
3) compare clinical characteristics and outcomes be-
tween patients receiving triple therapy with clopi-
dogrel versus prasugrel.sponsored by Daiichi-Sankyo, Inc., and Lilly USA. The Duke Clinical Researc
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STUDY POPULATION. The TRANSLATE-ACS
study design has been previously described
(10). Brieﬂy, STEMI and non-STEMI patients
treated with PCI and a P2Y12 receptor inhibi-
tor during the index MI hospitalization were
included. Patients who were unable to pro-
vide written informed consent for longitudi-
nal follow-up were excluded. Because the
main intent of the study was to observe lon-
gitudinal antiplatelet therapy use in routine
clinical practice, patients who were partici-
pating in another research study that speci-
ﬁed use of either an investigational or
approved P2Y12 receptor inhibitor within the
ﬁrst 12 months post-MI were excluded (10).
As TRANSLATE-ACS was an observational
study, all treatment decisions were left to the
discretion of the individual treating physi-
cians in accordance with practice guideline recom-
mendations and local standards of care. The
TRANSLATE-ACS study received approval from the
Duke University Institutional Review Board, as well
as the institutional review boards of all participating
sites. All subjects provided written informed consent.
Between April 2010 and October 2012, 12,365 acute
MI patients treated at 233 hospitals in the United
States with PCI were enrolled in the TRANSLATE-ACS
study. For the purpose of this analysis, we consid-
ered only patients who were discharged on DAPT
(aspirin plus either clopidogrel or prasugrel) or triple
therapy (DAPT plus any of the following oral antico-
agulants approved for clinical use during the study
period: warfarin, dabigatran, or rivaroxaban). We
excluded patients who died in-hospital, patients
discharged on other antiplatelet or anticoagulant
combinations, and patients discharged on none of
these medications (Figure 1). Our ﬁnal study popula-
tion included 11,756 acute MI patients discharged
from 233 U.S. hospitals.h Institute is the coordinating center for this study,
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FIGURE 1 Study Population
Shown is the initial study population, through exclusions, to the ﬁnal study population. Dual-C ¼ dual antiplatelet therapy with clopidogrel;
dual-P ¼ dual antiplatelet therapy with prasugrel; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; TRANSLATE-ACS ¼
Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary
Syndrome; triple-C ¼ triple therapy with clopidogrel; triple-P ¼ triple therapy with prasugrel.
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1882DATA COLLECTION AND STUDY ENDPOINTS. Base-
line clinical characteristics, demographics, past
medical history, in-hospital antiplatelet therapy or
antithrombotic therapy use, laboratory studies, PCI
data, and discharge medications were abstracted
from the medical record or patient interviews into
the TRANSLATE-ACS data collection form using
standardized data elements and deﬁnitions (10). Data
were screened upon entry, and only those meeting
pre-determined criteria for completeness and accu-
racy were entered into the database for analysis.
Post-discharge study follow-up was conducted
via centralized telephone interviews by trainedpersonnel at the Duke Clinical Research Institute
(Durham, North Carolina) at 6 weeks and 6, 12, and
15 months. The primary outcomes of this analysis
were post-discharge bleeding and major adverse
cardiovascular events (MACE) during the 6-month
follow-up period after the index MI hospitalization.
In this analysis, bleeding was deﬁned using Bleeding
Academic Research Consortium (BARC) criteria (11).
Bleeding events involving a rehospitalization (at least
an overnight stay regardless of inpatient admission,
observation, or emergency department stay only
status) were independently validated by study phy-
sicians at the Duke Clinical Research Institute on
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 4 , 2 0 1 5 Jackson et al.
D E C E M B E R 2 1 , 2 0 1 5 : 1 8 8 0 – 9 Outcomes of AMI Patients
1883the basis of review of medical records and classiﬁed
as BARC bleeding types 2 through 5. Bleeding events
involving rehospitalization were also classiﬁed
using the GUSTO (Global Use of Strategies to Open
Occluded Arteries) criteria; moderate/severe bleeding
was deﬁned as intracranial hemorrhage, bleeding
that caused hemodynamic compromise requiring
intervention, or bleeding that required blood trans-
fusion (12). Patient-reported–only bleeding events
that did not necessarily involve an overnight in-
hospital stay were collected during follow-up tele-
phone interviews with the question: “Since your
discharge from the hospital on (insert discharge date)
or last interview on (insert date), have you experi-
enced any severe unexplained bruising or any
bleeding?” Patient-reported–only bleeding events
were classiﬁed as BARC type 1 or 2 depending on
whether the bleeding prompted the patient to seek
clinical evaluation (BARC type 1 bleeding is deﬁned
as bleeding that is not actionable and does not cause
the patient to seek unscheduled performance of
studies, hospitalization, or treatment by a health care
professional). MACE were deﬁned as a composite of
death, MI, unplanned revascularization, or stroke at 6
months; all MACE events were independently adju-
dicated by study physicians via review of relevant
medical records using protocol-speciﬁed endpoint
deﬁnitions (10).
STATISTICAL METHODS. Patients were divided into
1 of the following 4 groups according to the speciﬁc
antiplatelet and anticoagulant medications pre-
scribed at discharge: 1) triple therapy with clopi-
dogrel (triple-C: aspirin þ anticoagulant þ
clopidogrel); 2) triple therapy with prasugrel (triple-
P: aspirin þ anticoagulant þ prasugrel); 3) DAPT with
clopidogrel (dual-C: aspirin þ clopidogrel); and 4)
DAPT with prasugrel (dual-P: aspirin þ prasugrel).
We compared baseline and in-hospital characteris-
tics between these groups. Categorical variables
were summarized by counts and percentages and
compared using the Pearson chi-square test or
Fisher exact test. Continuous variables were sum-
marized by median, 25th and 75th percentiles, and
compared using Kruskal-Wallis tests. Poisson
regression models, with generalized estimating
equations to account for within hospital clustering
using inverse probability-weighted propensity score
adjustment, were performed to compare any BARC
bleeding between treatment groups. Additionally,
logistic models with generalized estimating equa-
tions, again using inverse probability-weighted
propensity score adjustment, were conducted to
examine BARC bleeding as an ordinal outcome(involved rehospitalization vs. patient-reported–
only vs. no bleeding). Inverse probability-weighted
adjusted Cox proportional hazard modeling was
used to compare risks of GUSTO moderate/severe
bleeding and MACE. Follow-up began at the date of
discharge and was censored at the ﬁrst BARC
bleeding event date (if known) or the date of the
interview during which the event was reported, the
death date, or the 6-month interview date. Pro-
pensity score models were created for each of the
following comparisons: 1) triple-C versus dual-C; 2)
triple-P versus dual-P; and 3) triple-C versus triple-P
(C statistics: triple-P vs. triple-C [0.725]; triple-P vs.
dual-P [0.834]; triple-C vs. dual-C [0.835]) (Online
Tables 1 to 3). Covariate selection was based on
previous risk models, signiﬁcant univariable com-
parison results, and clinical judgment. Pre- and
post-inverse probability-weighted balance of all
covariates between the different exposures was
assessed using Cramer’s Phi for categorical variables
and R-squared for continuous variables (Online
Appendix, Online Figures 1 and 2). For the compar-
ison of triple-C versus triple-P, modeling was per-
formed on the subset of 327 patients (n ¼ 77 for
prasugrel and n ¼ 250 for clopidogrel) who had
overlapping propensity scores (Online Figure 3). All
statistical analyses were performed at the Duke
Clinical Research Institute using SAS software
(version 9.3, SAS Institute, Cary, North Carolina).
RESULTS
PATIENT AND BASELINE CHARACTERISTICS. Among
the 11,756 acute MI patients treated with PCI, 617
patients (5%) were discharged on triple therapy
(Figure 1). Triple therapy with clopidogrel (triple-C)
was used in 526 patients, whereas triple therapy with
prasugrel (triple-P) was used in 91 (4.5% and 0.8% of
the overall study population, respectively). Among
patients discharged on triple therapy, warfarin was
the predominant oral anticoagulant used in 572 pa-
tients (93%), whereas novel oral anticoagulants
(dabigatran or rivaroxaban) were used in 45 patients.
Among patients discharged on DAPT alone, 7,715
(66% of the overall study population) were treated
with clopidogrel (dual-C) and 3,424 (29%) received
prasugrel (dual-P).
Prior to admission, 347 (3%) patients were on home
oral anticoagulant therapy. The indications for anti-
coagulation were: prosthetic valve (n ¼ 26, 7%),
venous thromboembolism (n ¼ 69, 20%), atrial
ﬁbrillation/atrial ﬂutter (n ¼ 200, 58%), other (n ¼ 48,
14%), and missing (n ¼ 4, 1%). Among patients on
home anticoagulant therapy prior to admission,
TABLE 1 Baseline Characteristics of the Study Population
Triple-C vs. Dual-C
p Value
Triple-P vs. Dual-P
p Value
Triple-C vs. Triple-P
p Value(n ¼ 526) (n ¼ 7,715) (n ¼ 91) (n ¼ 3,424) (n ¼ 526) (n ¼ 91)
Demographics
Age, yrs 66 (56–75) 61.0 (53–70) <0.0001 57 (50–65) 56.0 (50–63) 0.28 66 (56–75) 57 (50–65) <0.0001
Male 390 (74.1) 5,355 (69.4) 0.02 79 (86.8) 2,675 (78.1) 0.05 390 (74.1) 79 (86.8) 0.01
White race 485 (92.9) 6,733 (88.0) 0.001 80 (87.9) 3,028 (89.0) 0.74 485 (92.9) 80 (87.9) 0.1
Past medical history
Prior MI 132 (25.3) 1,602 (20.9) 0.02 21 (23.1) 522 (15.3) 0.04 132 (25.3) 21 (23.1) 0.65
Prior PCI 120 (23.0) 1,737 (22.7) 0.87 20 (22.0) 649 (19.0) 0.48 120 (23.0) 20 (22.0) 0.83
Prior CABG 73 (14.0) 812 (10.6) 0.02 6 (6.6) 197 (5.8) 0.75 73 (14.0) 6 (6.6) 0.05
Prior stroke/TIA 57 (10.8) 514 (6.7) 0.0003 1 (1.1) 57 (1.7) 0.68 57 (10.8) 1 (1.1) 0.003
PAD 50 (9.6) 558 (7.3) 0.05 7 (7.7) 122 (3.6) 0.04 50 (9.6) 7 (7.7) 0.57
Diabetes 148 (28.4) 2,064 (27.0) 0.49 21 (23.1) 833 (24.5) 0.76 148 (28.4) 21 (23.1) 0.30
Hypertension 386 (74.0) 5,287 (69.1) 0.02 48 (52.8) 2,100 (61.7) 0.08 386 (74.0) 48 (52.8) <0.0001
Current/recent smoker 156 (29.9) 2,954 (38.6) <0.0001 29 (31.9) 1,373 (40.4) 0.10 156 (29.9) 29 (31.9) 0.70
GI/GU bleed in prior 6 months 10 (1.9) 83 (1.1) 0.08 2 (2.2) 27 (0.8) 0.14 10 (1.9) 2 (2.2) 0.85
Atrial ﬁbrillation/ﬂutter 159 (30.3) 296 (3.8) <0.0001 13 (14.3) 70 (2.1) <0.0001 159 (30.3) 13 (14.3) 0.002
Heart failure 83 (15.9) 489 (6.4) <0.0001 7 (7.7) 101 (3.0) 0.01 83 (15.9) 7 (7.7) 0.04
Admission features
STEMI 292 (55.5) 3,755 (48.7) 0.002 66 (72.5) 1,991 (58.2) 0.01 292 (55.5) 66 (72.5) 0.002
Weight, kg 88.0 (76–104) 86.4 (75–101) 0.20 90.9 (82–105) 90.9 (79–105) 0.70 88.0 (76–104) 90.9 (82–105) 0.10
Heart rate, beats/min 80 (67–94) 76 (65–88) <0.0001 80 (68–92) 77 (66–90) 0.07 80 (67–94) 80 (68–92) 0.77
Systolic BP, mm Hg 136 (117–155) 139 (121–158) 0.003 139 (123–160) 140 (122–160) 0.81 136 (117–155) 139 (123–160) 0.17
Cardiogenic shock 18 (3.5) 152 (2.0) 0.02 3 (3.3) 71 (2.1) 0.43 18 (3.5) 3 (3.3) 0.93
HF within 2 weeks 72 (14.0) 535 (7.1) <0.0001 12 (13.2) 146 (4.3) <0.0001 72 (14.0) 12 (13.2) 0.85
In-hospital characteristics
Multivessel PCI 52 (10.0) 826 (10.8) 0.56 6 (6.6) 329 (9.7) 0.32 52 (10.0) 6 (6.6) 0.31
Drug-eluting stent use 306 (58.9) 5,297 (69.4) <0.0001 67 (73.6) 2,585 (76.2) 0.58 306 (58.9) 67 (73.6) 0.001
Discharge aspirin >81 mg 180 (34.2) 5,259 (68.2) <0.0001 40 (44.0) 2,187 (63.9) <0.0001 180 (34.2) 40 (44.0) 0.07
In-hospital major bleeding 24 (4.6) 247 (3.2) 0.09 8 (8.8) 94 (2.8) 0.001 24 (4.6) 8 (8.8) 0.09
In-hospital stroke 1 (0.2) 11 (0.1) 0.78 2 (2.2) 1 (0.03) <0.0001 1 (0.2) 2 (2.2) 0.01
Values are median (interquartile range) or n (%).
BP ¼ blood pressure; CABG ¼ coronary artery bypass graft surgery; dual-C ¼ dual antiplatelet therapy with clopidogrel; dual-P ¼ dual antiplatelet therapy with prasugrel; GI/GU ¼ gastrointestinal/
genitourinary; HF¼ heart failure; MI¼myocardial infarction; PAD ¼ peripheral artery disease; PCI ¼ percutaneous coronary intervention; STEMI¼ ST-segment elevation myocardial infarction; TIA¼ transient
ischemic attack; triple-C ¼ triple therapy with clopidogrel; triple-P ¼ triple therapy with prasugrel.
TABLE 2
Treatmen
Compa
Triple-C v
Triple-P v
Triple-P v
Values are
group as the
adjustment.
BARC ¼ B
ratio; other
Jackson et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 4 , 2 0 1 5
Outcomes of AMI Patients D E C E M B E R 2 1 , 2 0 1 5 : 1 8 8 0 – 9
1884215 (62%) were discharged on triple-C, 16 (5%) were
discharged on triple-P, 104 (30%) were discharged on
dual-C, and 12 (3%) were discharged on dual-P.
Overall, 231 of the 617 (37%) patients were dis-
charged on triple therapy, and 116 of the 11,139 (1.0%)Comparison of Any BARC-Deﬁned Bleeding Between
t Groups
rison* Frequency
Adjusted IRR†
(95% CI) p Value
s. dual-C 151 (28.7) 1,521 (19.7) 1.68 (1.29–2.18) 0.0001
s. dual-P 35 (38.5) 914 (26.7) 1.88 (1.10–3.20) 0.0202
s. triple-C 30 (39.0) 61 (24.4) 2.37 (1.36–4.15) 0.003
n (%) unless otherwise indicated. *All comparisons designate the second treatment
reference group. †Adjusted results based on inverse probability weighted propensity
leeding Academic Research Consortium; CI ¼ conﬁdence interval; IRR ¼ incident rate
abbreviations as in Table 1.patients discharged on DAPT only were taking an oral
anticoagulant prior to admission.
Baseline characteristics of the study cohort are
shown according to discharge treatment group in
Table 1. Dual-C patients were younger than those
treated with triple-C; however, there was minimal age
difference between dual- and triple-P patients. Similar
to the overall results from the TRANSLATE-ACS study
(13), patients treated with prasugrel were younger
and were more likely to be male than those treated
with clopidogrel, regardless of oral anticoagulant use.
In general, patients treated with triple therapy had a
higher prevalence of cardiovascular comorbidities
such as prior MI, revascularization, and heart failure,
and were more likely to present with cardiogenic
shock or heart failure compared with patients treated
with DAPT, irrespective of the P2Y12 receptor inhibitor
used. Rates of STEMI presentation and drug-eluting
stent use were higher among patients treated
TABLE 3 Comparison of Bleeding Outcomes Between Treatment Groups
With Bleeding as an Ordinal Outcome: Rehospitalized Bleeding Versus
No Bleeding, and Patient-Reported–Only Bleeding Versus No Bleeding
Comparison* Frequency OR (95% CI)† p Value
Rehospitalized bleeding
Triple-C vs. dual-C 46 (10.9) vs. 217 (3.4) 3.13 (1.97–4.96) <0.0001
Triple-P vs. dual-P 6 (9.7) vs. 71 (2.8) 4.91 (1.36–17.7) 0.0150
Triple-P vs. triple-C 4 (7.8) vs. 16 (7.8) 0.62 (0.20–1.93) 0.4127
Patient-reported–only
bleeding
Triple-C vs. dual-C 105 (21.9) vs. 1304 (17.4) 1.40 (1.03–1.91) 0.0335
Triple-P vs. dual-P 29 (34.2) vs. 843 (25.1) 1.56 (0.85–2.86) 0.1478
Triple-P vs. triple-C 26 (35.6) vs. 45 (19.2) 3.19 (1.52–6.66) 0.0021
Values are n (%) unless otherwise indicated. *All comparisons designate the second treatment
group as the reference group. †Adjusted results based on inverse probability weighted propensity
adjustment.
OR ¼ odds ratio; other abbreviations as in Tables 1 and 2.
TABLE 4 Frequency of Individual BARC Subtype Bleeding Events
Comparison* Frequency
Unadjusted
p Value
Adjusted IRR†
(95% CI)
Adjusted
p Value
Patient-reported–only bleeding
BARC type 1
Triple-C vs. dual-C 61 (11.6) 779 (10.1) 0.1042 0.90 (0.60–1.33) 0.5869
Triple-P vs. dual-P 22 (24.2) 517 (15.1) 0.0065 1.97 (0.99–3.91) 0.0528
Triple-P vs. triple-C 19 (24.7) 24 (9.6) 0.0002 3.18 (1.63–6.18) 0.0007
BARC type 2
Triple-C vs. dual-C 101 (19.2) 835 (10.8) <0.0001 2.06 (1.50–2.82) <0.0001
Triple-P vs. dual-P 25 (27.5) 526 (15.4) 0.0003 1.56 (0.86–2.84) 0.1446
Triple-P vs. triple-C 23 (29.9) 44 (17.6) 0.0187 2.43 (1.33–4.44) 0.0038
Bleeding involving rehospitalization
BARC type 2
Triple-C vs. dual-C 26 (4.9) 108 (1.4) <0.0001 3.26 (1.64–6.47) 0.0007
Triple-P vs. dual-P 5 (5.5) 41 (1.2) 0.0006 —
Triple-P vs. triple-C 3 (3.9) 10 (4.0) 0.9630 —
BARC type 3
Triple-C vs. dual-C 23 (4.4) 120 (1.6) <0.0001 3.39 (1.82–6.30) 0.0001
Triple-P vs. dual-P 1 (1.1) 33 (1.0) 0.8651 —
Triple-P vs. triple-C 1 (1.3) 6 (2.4) 0.5475 —
BARC type 4
Triple-C vs. dual-C 0 (0.0) 4 (0.05) — —
Triple-P vs. dual-P 0 (0.0) 0 (0.0) — —
Triple-P vs. triple-C 0 (0.0) 0 (0.0) — —
BARC type 5
Triple-C vs. dual-C 1 (0.2) 5 (0.06) 0.3278 —
Triple-P vs. dual-P 0 (0.0) 0 (0.0) — —
Triple-P vs. triple-C 0 (0.0) 0 (0.0) — —
Values are n (%) unless otherwise speciﬁed. *All comparisons designate the second treatment group as the
reference group. †Adjusted results based on inverse probability weighted propensity adjustment.
Abbreviations as in Tables 1 and 2.
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1885with prasugrel regardless of oral anticoagulant use.
Drug-eluting stents were used in 59% of patients
discharged on triple-C and 74% among patients dis-
charged on triple-P. Notably, an aspirin dose >81 mg
was prescribed in approximately one-third of patients
discharged on triple therapy (44% among prasugrel-
treated and 34% among clopidogrel-treated patients)
and approximately two-thirds of patients discharged
on dual therapy. Overall, >4% of patients were lost to
follow-up at 6 months and >5% at 12 months for each
discharge group.
ANY BARC-DEFINED BLEEDING. At 6 months post-
discharge, triple-C was associated with a signiﬁ-
cantly higher risk of any BARC-deﬁned bleeding
compared with dual-C after multivariable analysis
(28.7% vs. 19.7%, adjusted incidence rate ratio [IRR]:
1.68, 95% conﬁdence interval [CI]: 1.29 to 2.18;
p ¼ 0.0001) (Table 2). Similarly, triple-P was associ-
ated with signiﬁcantly higher any BARC bleeding
compared with dual-P (38.5% vs. 26.7%, adjusted IRR:
1.88, 95% CI: 1.10 to 3.20; p ¼ 0.02). Among patients
treated with triple therapy, triple-P was associated
with signiﬁcantly higher bleeding compared with
triple-C (39.0% vs. 24.4%, adjusted IRR: 2.37, 95% CI:
1.36 to 4.15; p ¼ 0.003).
BLEEDING INVOLVING REHOSPITALIZATION AND
PATIENT-REPORTED–ONLY BLEEDING. Bleeding events
were stratiﬁed into those that involved rehospitali-
zation and those that were patient-reported only.
As shown in Table 3, triple therapy was associated
with signiﬁcantly higher risks of rehospitalized
bleeding compared with DAPT, regardless of P2Y12
receptor inhibitor choice. However, there was no
signiﬁcant difference between triple-P and -C
(adjusted odds ratio [OR]: 0.62, 95% CI: 0.20 to
1.93) for bleeding involving rehospitalization.
Triple-P was associated with signiﬁcantly higher
adjusted risk of patient-reported–only bleeding than
triple-C (adjusted OR: 3.19, 95% CI: 1.52 to 6.66;
p ¼ 0.002).
BLEEDING SUBTYPES AND SEVERITY. Bleeding events
that were patient-reported only and did not involve
rehospitalization were classiﬁed into BARC type 1
(not requiring patient to solicit medical attention)
and BARC type 2 (prompted evaluation). There was no
signiﬁcant difference between triple therapy versus
DAPT groups for BARC type 1 bleeding (Table 4),
but triple therapy was associated with signiﬁcantly
higher BARC type 2 patient-reported–only bleeding
for triple- compared with dual-C (adjusted IRR: 2.06,
95% CI: 1.50 to 2.82; p < 0.0001). Among patients on
triple therapy, triple-P was associated with signiﬁ-
cantly higher patient-reported bleeding than triple-C,regardless of BARC type. Bleeding events involving
rehospitalization were classiﬁed into BARC types 2
through 5 with event rates shown in Table 4. For
comparisons with low event rates for BARC bleeding
types 3 through 5, adjusted analyses were not
performed.
TABLE 5 Composite for 6-Month MACE
Comparison* Frequency
Adjusted HR†
(95% CI) Adjusted p Value
Triple-C vs. dual-C 19 (7.9) 681 (8.9) 1.10 (0.73–1.66) 0.6346
Triple-P vs. dual-P 10 (13.1) 239 (7.0) 2.08 (0.94–4.62) 0.0720
Triple-P vs. triple-C 10 (13.1) 19 (7.9) 1.53 (0.65–3.61) 0.3328
Values are n (%). *All comparisons designate the second treatment group as the reference group. †Adjusted
results based on inverse probability weighted propensity adjustment.
HR ¼ hazard ratio; MACE ¼ major adverse cardiac events; all other abbreviations as in Tables 1 and 2.
TABLE 6 Kaplan-Me
Treatment Group
Outcome E
Death
Myocardial
infarction
Stroke
Unplanned
revascularization
Abbreviations as in Tables
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1886Overall rates of GUSTO moderate/severe bleeding
within 6 months after acute MI were low. Among
clopidogrel-treated patients, GUSTO moderate/severe
bleeding occurred in 21 patients (4.1%) treated
with triple-C versus 109 patients (1.4%) treated with
dual-C (adjusted hazard ratio [HR]: 3.31, 95% CI: 1.49
to 7.37). One triple-P patient (1.1%) developed GUSTO
moderate/severe bleeding by 6-month follow-up
compared with 26 patients (0.8%) treated with
dual-P.
MAJOR ADVERSE CARDIOVASCULAR EVENTS. The
comparisons of MACE between treatment groups are
shown in Tables 5 and 6, as well as in Figures 2A to 2C.
There were no statistically signiﬁcant differences in
risk-adjusted MACE between groups.
BLEEDING AND ISCHEMIC OUTCOMES ON THE BASIS
OF ADMISSION ORAL ANTICOAGULANT STATUS.
Among patients who were discharged on triple ther-
apy (n ¼ 617), 231 (37%) were on oral anticoagulant
therapy prior to admission for their index MI. There
was no signiﬁcant association between oral anti-
coagulation use prior to admission versus no home
oral anticoagulation use and MACE at 6 months (HR:
1.07, 95% CI: 0.60 to 1.91; p ¼ 0.81). In addition, there
was no signiﬁcant association for either any
BARC-deﬁned bleeding (HR: 1.01, 95% CI: 0.66 to 1.57;
p ¼ 0.95) or ordinal BARC bleeding at 6 months
(patient-reported bleeding vs. no bleeding: OR: 1.01,
95% CI: 0.57 to 1.76; p ¼ 0.98; validated bleedingier Event Rates for MACE Components at 6 Months Per Discharge
Triple-C Triple-P Dual-C Dual-P
vents Rate (%) Events Rate (%) Events Rate (%) Events Rate (%)
27 5.2 1 1.1 128 1.7 21 0.6
23 4.5 2 2.2 225 3.0 60 1.8
4 0.8 2 2.2 37 0.5 10 0.3
28 5.5 11 12.3 478 6.3 190 5.6
1 and 5.vs. no bleeding: OR: 1.17, 95% CI: 0.52 to 2.60;
p ¼ 0.71).
DISCUSSION
The TRANSLATE-ACS study offers a unique oppor-
tunity to examine the longitudinal risks of oral anti-
coagulant use among a contemporary cohort of MI
patients treated with PCI and either clopidogrel or
prasugrel in the United States. In this study, 617 pa-
tients were discharged on triple therapy; of these, 526
patients were treated with clopidogrel and 91 were
treated with prasugrel. Our ﬁndings suggest that
acute MI patients discharged on triple therapy had a
greater risk of bleeding than those discharged on dual
therapy, regardless of which P2Y12 receptor inhibitor
was used. Among patients discharged on triple ther-
apy, the use of prasugrel was associated with a higher
risk of bleeding than clopidogrel. This association
was largely driven by an increase in patient-re-
ported–only bleeding; we observed no signiﬁcant
difference in the risk of bleeding requiring rehospi-
talization between these 2 groups. Finally, there was
no signiﬁcant difference in the composite risk of
MACE between treatment groups.
Expert consensus documents have provided rec-
ommendations on antithrombotic therapy regimens
for patients with recent MI and/or PCI and atrial
ﬁbrillation based on assessments of the need
for prophylaxis against stroke, stent thrombosis, or
other MACE (14). Yet, to date, most studies evaluating
bleeding and cardiovascular outcomes associated
with triple therapy have been nonrandomized
in design, predominantly retrospective, and mostly in
the setting of clopidogrel use (15–17). Sorensen et al.
(18) demonstrated that in MI patients, the yearly
incidence bleeding requiring rehospitalization was
3.7% for aspirin plus clopidogrel versus 12.0% for
triple therapy. Among patients with both MI and
atrial ﬁbrillation, antithrombotic intensiﬁcation was
similarly associated with increased bleeding risk.
Relative to aspirin alone, the HR was 1.22 for aspirin þ
clopidogrel, 1.46 for aspirin þ warfarin, and 1.65
for aspirin þ clopidogrel þ warfarin (19).
Prasugrel is a higher-potency P2Y12 receptor in-
hibitor proven to have superior efﬁcacy in reducing
downstream cardiovascular events when compared
with clopidogrel. Nonetheless, prasugrel is associ-
ated with a higher risk of bleeding (9), which leads
to hesitation for its use with oral anticoagulant
therapy. Our study showed that prasugrel was
received in approximately 1 in 7 patients (15%) on
triple therapy, and approximately 1 in 3 patients
(31%) on DAPT. This ﬁnding suggests that physicians
FIGURE 2 Kaplan-Meier Event Rates at 6 Months Post-Discharge
Kaplan-Meier event rates at 6 months post-discharge for: (A) triple-C versus dual-C;
(B) triple-P versus dual-P; and (C) triple-C versus triple-P. MACE ¼ major adverse cardiac
events; other abbreviations as in Figure 1.
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1887are less likely to add prasugrel to an oral anticoag-
ulant and more likely to choose clopidogrel when
prescribing DAPT with an oral anticoagulant. To
date, Sarafoff et al. (20) described the largest cohort
of patients treated with prasugrel and an oral anti-
coagulant. In this single-center cohort of patients
undergoing drug-eluting stent implantation and
discharged on oral anticoagulation, 21 of 377 patients
received prasugrel (20). Prasugrel-treated patients
had signiﬁcantly higher rates of Thrombolysis In
Myocardial Infarction major and minor bleeding at
6 months compared with clopidogrel-treated pa-
tients (6 [28.6%] vs. 24 [6.7%]; adjusted HR: 3.2, 95%
CI: 1.1 to 9.1). Of the 377 patients on triple therapy in
this study, only 139 (37%; 14 on prasugrel and 125
on clopidogrel) presented with acute coronary
syndrome.
Our cohort is a larger sample of acute MI patients
treated with PCI at more than 200 hospitals in
the United States. In a previous analysis of the
TRANSLATE-ACS study, patients discharged on
higher-potency P2Y12 receptor inhibitors were shown
to be more likely to have early post-discharge
bleeding than patients discharged on clopidogrel;
however, the majority of bleeding events were
patient-reported only and did not require rehospi-
talization (21). In our analysis of patients discharged
on oral anticoagulation therapy, we again observed a
higher risk of bleeding when patients were concur-
rently treated with prasugrel versus clopidogrel.
When bleeding events were divided into those
requiring rehospitalization versus those that did not,
we again demonstrated that the increase in bleeding
seen with prasugrel was primarily driven by more
minor patient-reported–only bleeding not requiring
rehospitalization. Although our cohort size is still
modest, our ﬁndings are reassuring in that we
observed no signiﬁcant difference in rehospitalized
bleeding risk between prasugrel and clopidogrel, and
only 1 of 91 patients on triple-P developed GUSTO
moderate/severe bleeding. Although, the rate of
MACE was higher for patients discharged on triple-P
compared with triple-C, we found no signiﬁcant dif-
ferences after adjustment. Nevertheless, given that
patients receiving triple therapy are less likely to be
prescribed prasugrel, we may not be fully accounting
for selection bias in this observational study. Further
investigation is needed to elucidate speciﬁc sub-
groups of patients for whom triple therapy with
prasugrel is preferable or cautioned.
Prior studies have shown the risk of bleeding
to be higher with triple therapy compared with
DAPT (18,22). In the TRANSLATE-ACS study, we
found a similar association between increased risk of
PERSPECTIVES
WHAT IS KNOWN? Prior studies have shown sig-
niﬁcant bleeding risk among MI patients receiving PCI
and treated with triple therapy (i.e., oral anticoagu-
lant, P2Y12 receptor inhibitor, and aspirin).
WHAT ISNEW?Wefound that amongMI patients, the
addition of an oral anticoagulant was associated with a
signiﬁcantly greater risk of any BARC-deﬁned bleeding
relative to DAPT, regardless of which P2Y12 receptor
inhibitor was selected. Among patients on triple ther-
apy, prasugrel use was associated with higher patient-
reported–only bleeding, but not bleeding requiring
rehospitalization, than clopidogrel-treated patients.
WHATISNEXT?Data from larger studies are needed to
determine the overall beneﬁt of different P2Y12 receptor
inhibitor regimens in patients requiring both systemic
anticoagulation and DAPT after a recent MI and/or PCI.
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1888bleeding and triple therapy, regardless of antiplatelet
agent choice. Although the TRANSLATE-ACS study
did not evaluate interventions to mitigate bleeding
risk in triple therapy patients, several points of
interest were noted. First, a substantial number of
patients treated with triple therapy were still dis-
charged on high-dose aspirin; therefore, lowering
concomitant aspirin dose may improve bleeding risk.
Second, in the WOEST (What is the Optimal Anti-
platelet and Anticoagulant Therapy in Patients With
Oral Anticoagulation and Coronary Stenting) trial,
DeWilde et al. (23) were able to show less bleeding
and no increase in the rate of thrombotic events when
clopidogrel was administered alone (without aspirin)
in conjunction with an oral anticoagulant, in com-
parison to triple therapy; however, the WOEST trial
primarily studied lower-risk patients, the majority of
whom did not have acute coronary syndromes, who
underwent PCI. Finally, rates of drug-eluting stent
use are also high in the anticoagulated population.
Minimizing the duration of antiplatelet therapy with
bare-metal stent selection may also improve bleeding
risk (24).
STUDY LIMITATIONS. First, TRANSLATE-ACS was a
voluntary observational study. Neither the selection
of P2Y12 receptor inhibitor therapy nor the designa-
tion of oral anticoagulant in combination with a P2Y12
receptor inhibitor was assigned in a randomized
manner. Therefore, despite rigorous multivariable
adjustment, residual selection bias and unmeasured
confounding likely remains. Second, although this is
the largest cohort described so far, the number of
patients that received triple-P was very low. Finally,
the small number of patients discharged on prasugrel
limits our ability to adjust for potential confounding
and attenuates the strength of the derived
conclusions.
CONCLUSIONS
In this observational study of contemporary MI pa-
tients treated with PCI and either clopidogrel orprasugrel, we observed a signiﬁcantly higher risk of
bleeding when an oral anticoagulant was added to
DAPT. Triple therapy with prasugrel was prescribed to
a select group of patients and was associated with a
higher risk of any BARC bleeding compared with triple
therapywith clopidogrel; however, this increase in risk
was primarily observed for patient-reported bleeding
that did not require rehospitalization. In contrast, we
observed no signiﬁcant difference in the risk of reho-
spitalized bleeding between triple-P and -C groups.
Data from larger studies are needed to determine the
overall beneﬁt of different P2Y12 receptor inhibitor
regimens in patients requiring both systemic anti-
coagulation and DAPT after a recent MI and/or PCI.
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